Neurogene Inc. (NGNE)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue under licensing agreements | - | - | 925 | |
| Research and development expenses | 19,366 | 16,285 | 15,744 | |
| General and administrative expenses | 6,715 | 5,895 | 5,315 | |
| Total operating expenses | 26,081 | 22,180 | 21,059 | |
| Loss from operations | -26,081 | -22,180 | -20,134 | |
| Interest income | 2,928 | 1,842 | 2,035 | |
| Interest expense | 1 | 3 | 4 | |
| Other expense | 74 | 19 | 533 | |
| Other income | 1,212 | 143 | 144 | |
| Net loss | -22,016 | -20,217 | -18,492 | |
| Net loss per share, basic (in dollars per share) | -1.05 | -1.19 | -1.09 | |
| Net loss per share, diluted (in dollars per share) | -1.05 | -1.19 | -1.09 | |
| Weighted-average shares of common stock outstanding, basic (in shares) | 21,055,378 | 16,953,443 | 16,941,524 | |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 21,055,378 | 16,953,443 | 16,941,524 | |